China’s Hengrui In-Licenses AMD Antibody Program From X-Body Biosciences
This article was originally published in The Pink Sheet Daily
Executive Summary
Hengrui becomes the first Chinese manufacturer to in-license an early stage MAb from a Western biopharma as it looks to develop an age-related macular degeneration therapy that could compete with Novartis/Roche’s Lucentis and Bayer/Regeneron’s Eylea.